Condition: AL Amyloidosis (AL) · t(11;14) Positive · Sponsor: Peking University People's Hospital
The goal of this study is to evaluate the efficacy and safety of Sonrotoclax combined Regimen in patients with t(11;14) AL amyloidosis. Participants will receive the Sonrotoclax Plus Dexamethasone regimen with or without Daratumumab for 12 cycles. The Hematologic Response, Organ Response, Survival, and Safety will be evaluated.
This description comes directly from the study's public registry record.
Yang Liu · +86 13716926210 · pkuphliuyang@bjmu.edu.cn
Always discuss trial participation with your own doctor first.
| Peking University First Hospital | Beijing, China | Recruiting |
| Peking University People's Hospital | Beijing, China | Recruiting |
| The first Affiliated Hospital of Xi'an Jiaotong University | Xi'an, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07335887